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Late Cerebral Events After
Carotid Artery StentingWe read with great interest the recent paper by Gen-
sicke et al. (1), which reported a 3-fold increased risk of
recurrence of stroke or transient ischemic attack at 6
months in symptomatic patients treated with carotid
artery stenting (CAS) and who showed new silent
ischemic cerebral lesions on diffusion-weighted mag-
netic resonance imaging after the endovascular pro-
cedure. This observation did not apply to patients
treated with carotid endoatherectomy (CEA). The
investigators discussed the possible role of vulnerable
plaques and the potential beneﬁts of longer and more
aggressive antiplatelet therapy. The study provided
highly valuable new scientiﬁc evidence that might
improve the current clinical outcomes of CAS and ge-
nerated a hypothesis that deserves intensive in-
vestigation. However, the previously published ICSS
(International Carotid Stenting Study) data provided
little information on the kind of stent that was used
(2). With cerebral protection, plaque coverage is acritical issue for CAS success; although CEA could
remove almost the entire plaque, carotid stents have a
free area between the struts where plaque prolapse
could happen, with a risk of late embolization (3). It is
well known that the free area surface varies according
to stent design, with signiﬁcant differences between
open- and closed-cell stents; the latter has better pla-
que coverage and a lower incidence of plaque prolapse
(4). Since the ICSS study was performed, new mesh-
covered stents with a small, free-cell area have
become available, which potentially could reduce late
embolization from the stent-covered plaque. A more
aggressive medical therapy in this subset of patients is
advisable, but carotid stent characteristics should be
taken into account when considering the global risk of
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Cerebral Events After Carotid Artery StentingDrs. Pacchioni, Ribichini, and Reimers raise an
important issue about the effects of stent design on
outcomes after carotid artery stenting. The stent
design used was reported for 119 of 124 patients
who underwent stenting for symptomatic carotid
stenosis in the ICSS-MRI (International Carotid
Stenting Study-Magnetic Resonance Imaging) sub-
study; 74 patients (62%) received an open-cell stent
